This inventor holds 3 USPTO granted patents. Top assignee: Bio-Technology General Corporation. Active years: 1992-1996.
Company Filing History:
Years Active: 1992-1996
Title: Hilla Locker-Galadi: Innovator in Genetic Engineering
Introduction
Hilla Locker-Galadi is a prominent inventor based in Jerusalem, Israel. She has made significant contributions to the field of genetic engineering, particularly in the development of expression vectors. With a total of 3 patents, her work has advanced the capabilities of gene expression in various biological systems.
Latest Patents
Hilla's latest patents include innovative expression vectors that utilize the lambdapl promoter and T.sub.1 T.sub.2 rRNA. These vectors are designed to enhance gene expression in suitable hosts containing the thermolabile repressor C.sub.I. The vectors are double-stranded DNA molecules that incorporate essential elements such as the promoter and operator P.sub.L O.sub.L from lambda bacteriophage, the N utilization site, and ribosomal binding sites. These advancements allow for the production of important proteins, including bovine, chicken, and porcine growth hormones, as well as human apolipoprotein E and human superoxide dismutase.
Career Highlights
Hilla Locker-Galadi has been associated with Bio-Technology General Corporation, where she has played a crucial role in research and development. Her innovative approaches have led to the construction of plasmids that facilitate the expression of various genes, showcasing her expertise in molecular biology and genetic engineering.
Collaborations
Hilla has collaborated with notable colleagues, including Marian Gorecki and Amos B Oppenheim. These partnerships have further enriched her research and contributed to the advancement of genetic engineering technologies.
Conclusion
Hilla Locker-Galadi's contributions to the field of genetic engineering through her innovative patents and collaborations highlight her as a key figure in advancing biotechnology. Her work continues to impact the scientific community and the development of new therapeutic solutions.